Literature DB >> 16299531

VSV-tumor selective replication and protein translation.

Glen N Barber1.   

Abstract

The emergence of vesicular stomatatis virus (VSV) as a potent antitumor agent has made a dissection of the molecular determinants of host-cell permissiveness to this virus an important objective. Such insight would not only enable the intelligent design of future generations of recombinant VSV vectors to combat disease, but may also resolve general features of cellular transformation that may be exploited by this virus, and perhaps other oncolytic viruses. The defective pathways underlining the oncolytic activity of VSV remain to be fully determined but recent data indicates that flaws in innate immune responses, involving the interferon (IFN) system, may commonly occur in tumor cells and thus play a large role in facilitating oncolysis. Aside from the IFN system, however, it is almost certain that other key cellular pathways may be similarly defective and therefore cooperatively contribute towards mediating rapid oncolytic virus activity. Recent data have indicated that defects in cancer cell translational regulation could be one area that may be exploited by VSV. Certainly, all viruses require cellular protein synthesis pathways to facilitate their replication and many have devised numerous mechanisms to ensure that viral mRNAs become translated at the expense of the host. Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299531     DOI: 10.1038/sj.onc.1209042

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  87 in total

1.  Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus.

Authors:  Stuart Bloor; Jonathan Maelfait; Rebekka Krumbach; Rudi Beyaert; Felix Randow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

2.  RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses.

Authors:  Debasis Panda; Anshuman Das; Phat X Dinh; Sakthivel Subramaniam; Debasis Nayak; Nicholas J Barrows; James L Pearson; Jesse Thompson; David L Kelly; Istvan Ladunga; Asit K Pattnaik
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 3.  Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase.

Authors:  Jean-François Gélinas; Guerline Clerzius; Eileen Shaw; Anne Gatignol
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Authors:  Candice Willmon; Rosa M Diaz; Phonphimon Wongthida; Feorillo Galivo; Timothy Kottke; Jill Thompson; Steven Albelda; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

Review 5.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

6.  Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.

Authors:  Justin C Paglino; Wells Andres; Anthony N van den Pol
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

7.  LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.

Authors:  Danit Finkelshtein; Ariel Werman; Daniela Novick; Sara Barak; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

8.  Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Authors:  Candice L Willmon; Vassiliki Saloura; Zvi G Fridlender; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Timothy Kottke; Mark Federspiel; Glen Barber; Steven M Albelda; Richard G Vile
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

9.  Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting.

Authors:  Elizabeth J Kelly; Rebecca Nace; Glen N Barber; Stephen J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.